Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3844766A + AS01E
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**GSK3844766A + AS01E** is a combination vaccine candidate for the prevention of moderate-to-severe lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in older adults[3][5][7]. The drug consists of the RSVPreF3 recombinant antigen (GSK3844766A) formulated with GSK’s proprietary AS01E adjuvant system to enhance the immune response in this population, which typically exhibits weaker immunity to vaccination. The vaccine is administered intramuscularly and has undergone Phase I/II clinical evaluation. Immunization stimulates robust neutralizing antibody and cellular responses against RSV, with AS01E boosting both magnitude and duration of immunity[3][4][5][7].
- Other names
- RSVPreF3 OA investigational vaccineRSVPreF-3 OA investigational vaccineRSVPreF 3 OA investigational vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)TLR4 (Toll-like receptor 4)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on GSK3844766A + AS01E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3844766A + AS01E.